Pharmacological properties of new heterocyclic derivatives of 1,5-benzodiazepine.
Sixteen new heterocyclic 1,5-benzodiazepine derivatives (compounds AN8-AN24) were screened for their central action. Compounds AN8-AN10 and AN17 strongly antagonized the action of pentetrazol, compounds AN10, AN14-AN17 and AN22 had potent antiserotonin properties, and compounds AN10, AN19, AN20 and AN23 markedly potentiated the action of DOPA.
D000818:Animals; D014151:Anti-Anxiety Agents; D001569:Benzodiazepines / Q000494:pharmacology*; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004347:Drug Interactions; D005260:Female; D006591:Hexobarbital / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012110:Reserpine / Q000037:antagonists & inhibitors; D012640:Seizures / Q000517:prevention & control; D012702:Serotonin Antagonists; D012890:Sleep / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects; D013997:Time Factors
D014151:Anti-Anxiety Agents; D012702:Serotonin Antagonists; D001569:Benzodiazepines; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D006591:Hexobarbital